Many of the currently available anti-parasitic and anti-fungal frontline drugs have severe limitations, including adverse side effects, complex administration, and increasing occurrence of resistance. The discovery and development of new therapeutic agents is a costly and lengthy process. Therefore, repurposing drugs with already established clinical application offers an attractive, fast-track approach for novel treatment options. In this study, we show that the anti-cancer drug candidate MitoTam, a mitochondria-targeted analog of tamoxifen, efficiently eliminates a wide range of evolutionarily distinct pathogens in vitro, including pathogenic fungi, Plasmodium falciparum, and several species of trypanosomatid parasites, causative agents of debilitating neglected tropical diseases. MitoTam treatment was also effective in vivo and significantly reduced parasitemia of two medically important parasites, Leishmania mexicana and Trypanosoma brucei, in their respective animal infection models. Functional analysis in the bloodstream form of T. brucei showed that MitoTam rapidly altered mitochondrial functions, particularly affecting cellular respiration, lowering ATP levels, and dissipating mitochondrial membrane potential. Our data suggest that the mode of action of MitoTam involves disruption of the inner mitochondrial membrane, leading to rapid organelle depolarization and cell death. Altogether, MitoTam is an excellent candidate drug against several important pathogens, for which there are no efficient therapies and for which drug development is not a priority.

Centre for Infectious Diseases Parasitology Heidelberg University Hospital Heidelberg Germany

Department of Parasitology Faculty of Science Charles Universitygrid 4491 8 BIOCEV Vestec Czech Republic

Department of Physiology Faculty of Science Charles Universitygrid 4491 8 Prague Czech Republic

Faculty of Science University of South Bohemia České Budějovice Czech Republic

Faculty of Sciences Charles Universitygrid 4491 8 Department of Parasitology Prague Czech Republic

Graduate Program in Areas of Basic and Applied Biology Instituto de Ciências Biomédicas Abel Salazar Universidade do Porto Portugal

Institute of Biotechnology Czech Academy of Sciences BIOCEV Vestec Czech Republic

Institute of Parasitology Biology Centre Czech Academy of Sciences České Budějovice Czech Republic

School of Pharmacy and Medical Science Griffith University Southport Queensland Australia

Zobrazit více v PubMed

Lee SM, Kim MS, Hayat F, Shin D. 2019. Recent advances in the discovery of novel antiprotozoal agents. Molecules 24. 10.3390/molecules24213886. PubMed DOI PMC

Monzote L, Siddiq A. 2011. Drug development to Protozoan Diseases. Open Med Chem J 5:1–3. 10.2174/1874104501105010001. PubMed DOI PMC

Andrews KT, Fisher G, Skinner-Adams TS. 2014. Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist 4:95–111. 10.1016/j.ijpddr.2014.02.002. PubMed DOI PMC

Murphy MP, Smith RAJ. 2007. Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations. Annu Rev Pharmacol Toxicol 47:629–656. 10.1146/annurev.pharmtox.47.120505.105110. PubMed DOI

Teixeira J, Soares P, Benfeito S, Gaspar A, Garrido J, Murphy MP, et al. . 2012. Rational discovery and development of a mitochondria-targeted antioxidant based on cinnamic acid scaffold. Free Radic Res 46. 10.3109/10715762.2012.662593. PubMed DOI

Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276:4588–4596. 10.1074/jbc.M009093200. PubMed DOI

Benien P, Benein P, Almuteri MA, Mehanna AS, D'Souza GGM. 2015. Synthesis of triphenylphosphonium phospholipid conjugates for the preparation of mitochondriotropic liposomes. Methods Mol Biol 1265:51–57. 10.1007/978-1-4939-2288-8_4. PubMed DOI

Du F, Min Y, Zeng F, Yu C, Wu S. 2014. A targeted and FRET-based ratiometric fluorescent nanoprobe for imaging mitochondrial hydrogen peroxide in living cells. Small 10:964–972. 10.1002/smll.201302036. PubMed DOI

Cairns AG, McQuaker SJ, Murphy MP, Hartley RC. 2015. Targeting mitochondria with small molecules: the preparation of MitoB and MitoP as exomarkers of mitochondrial hydrogen peroxide. Methods Mol Biol 1265:25–50. 10.1007/978-1-4939-2288-8_3. PubMed DOI

Terekhova NV, Tatarinov DA, Shaihutdinova ZM, Pashirova TN, Lyubina AP, Voloshina AD, Sapunova AS, Zakharova LY, Mironov VF. 2020. Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action. Bioorg Med Chem Lett 30:127234. 10.1016/j.bmcl.2020.127234. PubMed DOI

Kinnamon KE, Steck EA, Rane DS. 1979. A new chemical series active against African Trypanosomes: benzyltriphenylphosphonium salts. J Med Chem 22. 10.1021/jm00190a019. PubMed DOI

Fueyo González FJ, Ebiloma GU, Izquierdo García C, Bruggeman V, Sánchez Villamañán JM, Donachie A, Balogun EO, Inaoka DK, Shiba T, Harada S, Kita K, de Koning HP, Dardonville C. 2017. Conjugates of 2,4-dihydroxybenzoate and salicylhydroxamate and lipocations display potent antiparasite effects by efficiently targeting the Trypanosoma brucei and Trypanosoma congolense mitochondrion. J Med Chem 60:1509–1522. 10.1021/acs.jmedchem.6b01740. PubMed DOI

Alkhaldi AAM, Martinek J, Panicucci B, Dardonville C, Zíková A, de Koning HP. 2016. Trypanocidal action of bisphosphonium salts through a mitochondrial target in bloodstream form Trypanosoma brucei. Int J Parasitol Drugs Drug Resist 6:23–34. 10.1016/j.ijpddr.2015.12.002. PubMed DOI PMC

Long TE, Lu X, Galizzi M, Docampo R, Gut J, Rosenthal PJ. 2012. Phosphonium lipocations as antiparasitic agents. Bioorg Med Chem Lett 22:2976–2979. 10.1016/j.bmcl.2012.02.045. PubMed DOI PMC

Manzano JI, Cueto-Díaz EJ, Olías-Molero AI, Perea A, Herraiz T, Torrado JJ, Alunda JM, Gamarro F, Dardonville C. 2019. Discovery and pharmacological studies of 4-hydroxyphenyl-derived phosphonium salts active in a mouse model of visceral leishmaniasis. J Med Chem 62:10664–10675. 10.1021/acs.jmedchem.9b00998. PubMed DOI

Taladriz A, Healy A, Flores Pérez EJ, Herrero García V, Ríos Martínez C, Alkhaldi AAM, Eze AA, Kaiser M, de Koning HP, Chana A, Dardonville C. 2012. Synthesis and structure-activity analysis of new phosphonium salts with potent activity against African trypanosomes. J Med Chem 55:2606–2622. 10.1021/jm2014259. PubMed DOI

Jara JA, Castro-Castillo V, Saavedra-Olavarría J, Peredo L, Pavanni M, Jaña F, Letelier ME, Parra E, Becker MI, Morello A, Kemmerling U, Maya JD, Ferreira J. 2014. Antiproliferative and uncoupling effects of delocalized, lipophilic, cationic gallic acid derivatives on cancer cell lines. Validation in vivo in singenic mice. J Med Chem 57:2440–2454. 10.1021/jm500174v. PubMed DOI

Dong L, Gopalan V, Holland O, Neuzil J. 2020. Mitocans revisited: mitochondrial targeting as efficient anti-cancer therapy. Int J Mol Sci 21:7941. 10.3390/ijms21217941. PubMed DOI PMC

Rohlenova K, Sachaphibulkij K, Stursa J, Bezawork-Geleta A, Blecha J, Endaya B, Werner L, Cerny J, Zobalova R, Goodwin J, Spacek T, Alizadeh Pesdar E, Yan B, Nguyen MN, Vondrusova M, Sobol M, Jezek P, Hozak P, Truksa J, Rohlena J, Dong L-F, Neuzil J. 2017. Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2 high breast cancer. Antioxid Redox Signal 26:84–103. 10.1089/ars.2016.6677. PubMed DOI PMC

Jordan VC. 2003. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. 10.1038/nrd1031. PubMed DOI

Unten Y, Murai M, Koshitaka T, Kitao K, Shirai O, Masuya T, Miyoshi H. 2022. Comprehensive understanding of multiple actions of anticancer drug tamoxifen in isolated mitochondria. Biochim Biophys Acta Bioenerg 1863:148520. 10.1016/j.bbabio.2021.148520. PubMed DOI

Hubackova S, Davidova E, Rohlenova K, Stursa J, Werner L, Andera L, Dong L, Terp MG, Hodny Z, Ditzel HJ, Rohlena J, Neuzil J. 2019. Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death Differ 26:276–290. 10.1038/s41418-018-0118-3. PubMed DOI PMC

Hubackova S, Zobalova R, Dubisova M, Smigova J, Dvorakova S, Korinkova K. 2022. Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clin Transl Med. PubMed PMC

Vacurova E, Trnovska J, Svoboda P, Skop V, Endaya B, Novosadova V, et al. . 2022. Targeting mitochondria as a novel approach to treatment of metabolic diseases. Nat Commun. Forthcomin. PubMed

Stuart K, Brun R, Croft S, Fairlamb A, Gürtler RE, McKerrow J, Reed S, Tarleton R. 2008. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 118:1301–1310. 10.1172/JCI33945. PubMed DOI PMC

Field MC, Horn D, Fairlamb AH, Ferguson MAJ, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S, Gilbert IH. 2017. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol 15:217–231. 10.1038/nrmicro.2016.193. PubMed DOI PMC

Mesu VKBK, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, Delhomme S, Bernhard S, Kuziena W, Lubaki J-PF, Vuvu SL, Ngima PN, Mbembo HM, Ilunga M, Bonama AK, Heradi JA, Solomo JLL, Mandula G, Badibabi LK, Dama FR, Lukula PK, Tete DN, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. 2018. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 391:144–154. 10.1016/S0140-6736(17)32758-7. PubMed DOI

Dickie EA, Giordani F, Gould MK, Mäser P, Burri C, Mottram JC, Rao SPS, Barrett MP. 2020. New drugs for human African trypanosomiasis: a twenty first century success story. TropicalMed 5:29. 10.3390/tropicalmed5010029. PubMed DOI PMC

WHO. 2021. Malaria. Available: https://www.who.int/news-room/fact-sheets/detail/malaria#:~:text=Malaria%20is%20a%20life%2Dthreatening,at%20627%20000%20in%202020.

Dadar M, Tiwari R, Karthik K, Chakraborty S, Shahali Y, Dhama K. 2018. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update. Microb Pathog 117:128–138. Academic Press. 10.1016/j.micpath.2018.02.028. PubMed DOI

Maziarz EK, Perfect JR. 2016. Cryptococcosis. Infect Dis Clin North Am 30:179–206. 10.1016/j.idc.2015.10.006. PubMed DOI PMC

Grace E, Asbill S, Virga K. 2015. Naegleria fowleri: pathogenesis, diagnosis, and treatment options. Antimicrob Agents Chemother 59:6677–6681. 10.1128/AAC.01293-15. PubMed DOI PMC

Kot K, Łanocha-Arendarczyk NA, Kosik-Bogacka DI. 2018. Amoebas from the genus Acanthamoeba and their pathogenic properties. Ann Parasitol 64:299–308. PubMed

Ryan U, Hijjawi N, Feng Y, Xiao L. 2019. Giardia: an under-reported foodborne parasite. Int J Parasitol 49:1–11. 10.1016/j.ijpara.2018.07.003. PubMed DOI

Van Gerwen OT, Muzny CA. 2019. Recent advances in the understanding and management of of Trichomonas vaginalis infection. F1000Res 8:1666–1610. 10.12688/f1000research.20411.1. PubMed DOI PMC

Tachezy J. 2008. Hydrogenosomes and Mitosomes: mitochondria of Anaerobic Eukaryotes.

Kita K, Nihei C, Tomitsuka E. 2003. Parasite mitochondria as drug target: diversity and dynamic changes during the life cycle. Curr Med Chem 10:2535–2548. 10.2174/0929867033456549. PubMed DOI

Shingu-Vazquez M, Traven A. 2011. Mitochondria and fungal pathogenesis: drug tolerance, virulence, and potential for antifungal therapy. Eukaryot Cell 10:1376–1383. 10.1128/EC.05184-11. PubMed DOI PMC

Goldberg DE, Zimmerberg J. 2020. Hardly vacuous: the parasitophorous vacuolar membrane of malaria parasites. Trends Parasitol 36:138–146. 10.1016/j.pt.2019.11.006. PubMed DOI PMC

De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, Cameron S, Gilbert IH, Wyatt PG, Frearson JA, Fairlamb AH, Gray DW. 2013. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother 57:2913–2922. 10.1128/AAC.02398-12. PubMed DOI PMC

Don R, Ioset JR. 2014. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141:140–146. 10.1017/S003118201300142X. PubMed DOI

Wyllie S, Brand S, Thomas M, De Rycker M, Chung C-W, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko E-J, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG. 2019. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc Natl Acad Sci USA 116:9318–9323. 10.1073/pnas.1820175116. PubMed DOI PMC

Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367–1372. 10.1038/nbt.1511. PubMed DOI

Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J. 2016. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13:731–740. 10.1038/nmeth.3901. PubMed DOI

Arbon D, Ženíšková K, Mach J, Grechnikova M, Malych R, Talacko P, Sutak R. 2020. Adaptive iron utilization compensates for the lack of an inducible uptake system in Naegleria fowleri and represents a potential target for therapeutic intervention. Singer SM, editor. PLoS Negl Trop Dis 14:e0007759. 10.1371/journal.pntd.0007759. PubMed DOI PMC

Zíková A, Verner Z, Nenarokova A, Michels PAM, Lukeš J. 2017. A paradigm shift: the mitoproteomes of procyclic and bloodstream Trypanosoma brucei are comparably complex. PLoS Pathog 13:e1006679. 10.1371/journal.ppat.1006679. PubMed DOI PMC

Smith TK, Bringaud F, Nolan DP, Figueiredo LM. 2017. Metabolic reprogramming during the Trypanosoma brucei life cycle. F1000Res 6:683. 10.12688/f1000research.10342.1. PubMed DOI PMC

Schnaufer A, Clark-Walker GD, Steinberg AG, Stuart K. 2005. The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function. EMBO J 24:4029–4040. 10.1038/sj.emboj.7600862. PubMed DOI PMC

Nolan DP, Voorheis HP. 1992. The mitochondrion in bloodstream forms of Trypanosoma brucei is energized by the electrogenic pumping of protons catalysed by the F1F0-ATPase. Eur J Biochem 209:207–216. 10.1111/j.1432-1033.1992.tb17278.x. PubMed DOI

Surve S, Heestand M, Panicucci B, Schnaufer A, Parsons M. 2012. Enigmatic presence of mitochondrial complex I in Trypanosoma brucei bloodstream forms. Eukaryot Cell 11:183–193. 10.1128/EC.05282-11. PubMed DOI PMC

Poojari C, Wilkosz N, Lira RB, Dimova R, Jurkiewicz P, Petka R, Kepczynski M, Róg T. 2019. Behavior of the DPH fluorescence probe in membranes perturbed by drugs. Chem Phys Lipids 223:104784. 10.1016/j.chemphyslip.2019.104784. PubMed DOI

Grebowski J, Krokosz A, Puchala M. 2013. Membrane fluidity and activity of membrane ATPases in human erythrocytes under the influence of polyhydroxylated fullerene. Biochim Biophys Acta 1828:241–248. 10.1016/j.bbamem.2012.09.008. PubMed DOI

Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498–511. 10.1038/nature01097. PubMed DOI PMC

Verner Z, Čermáková P, Škodová I, Kriegová E, Horváth A, Lukeš J. 2011. Complex i (NADH:ubiquinone oxidoreductase) is active in but non-essential for procyclic Trypanosoma brucei. Mol Biochem Parasitol 175:196–200. 10.1016/j.molbiopara.2010.11.003. PubMed DOI

Trinconi CT, Miguel DC, Silber AM, Brown C, Mina JGM, Denny PW, Heise N, Uliana SRB. 2018. Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania. Int J Parasitol Drugs Drug Resist 8:475–487. 10.1016/j.ijpddr.2018.10.007. PubMed DOI PMC

Piñero TA, Landoni M, Duschak VG, Katzin AM, Couto AS. 2018. Effect of tamoxifen on the sphingolipid biosynthetic pathway in the different intraerythrocytic stages of the apicomplexa Plasmodium falciparum. Biochem Biophys Res Commun 497. 10.1016/j.bbrc.2018.02.183. PubMed DOI

Landoni M, Piñero T, Soprano LL, Garcia-Bournissen F, Fichera L, Esteva MI, Duschak VG, Couto AS. 2019. Tamoxifen acts on Trypanosoma cruzi sphingolipid pathway triggering an apoptotic death process. Biochem Biophys Res Commun 516:934–940. 10.1016/j.bbrc.2019.06.149. PubMed DOI

Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. 2007. Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother 51:1926–1933. 10.1128/AAC.01607-06. PubMed DOI PMC

Hierro-Yap C, Šubrtová K, Gahura O, Panicucci B, Dewar C, Chinopoulos C, Schnaufer A, Zíková A. 2021. Bioenergetic consequences of FoF1–ATP synthase/ATPase deficiency in two life cycle stages of Trypanosoma brucei. J Biol Chem 296:100357. 10.1016/j.jbc.2021.100357. PubMed DOI PMC

Mach J, Bíla J, Ženíšková K, Arbon D, Malych R, Glavanakovová M, Nývltová E, Sutak R. 2018. Iron economy in Naegleria gruberi reflects its metabolic flexibility. Int J Parasitol 48:719–727. 10.1016/j.ijpara.2018.03.005. PubMed DOI

Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, Carrington M, Depledge DP, Fischer S, Gajria B, Gao X, Gardner MJ, Gingle A, Grant G, Harb OS, Heiges M, Hertz-Fowler C, Houston R, Innamorato F, Iodice J, Kissinger JC, Kraemer E, Li W, Logan FJ, Miller JA, Mitra S, Myler PJ, Nayak V, Pennington C, Phan I, Pinney DF, Ramasamy G, Rogers MB, Roos DS, Ross C, Sivam D, Smith DF, Srinivasamoorthy G, Stoeckert CJ, Subramanian S, Thibodeau R, Tivey A, Treatman C, Velarde G, Wang H. 2010. TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res 38:D457–D462. 10.1093/nar/gkp851. PubMed DOI PMC

NCCLS. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard serving the world’s medical science community through voluntary consensus. Nccls.

Bateman A, Martin MJ, Orchard S, Magrane M, Agivetova R, Ahmad S, et al. . 2021. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res 49. 10.1093/nar/gkaa1100. PubMed DOI

Panigrahi AK, Zíková A, Dalley RA, Acestor N, Ogata Y, Anupama A, Myler PJ, Stuart KD. 2008. Mitochondrial complexes in Trypanosoma brucei: a novel complex and a unique oxidoreductase complex. Mol Cell Proteomics 7:534–545. 10.1074/mcp.M700430-MCP200. PubMed DOI

Šubrtová K, Panicucci B, Zíková A. 2015. ATPaseTb2, a unique membrane-bound FoF1-ATPase component, is essential in bloodstream and dyskinetoplastic trypanosomes. PLoS Pathog 11:e1004660. 10.1371/journal.ppat.1004660. PubMed DOI PMC

Doleželová E, Klejch T, Špaček P, Slapničková M, Guddat L, Hocková D, Zíková A. 2021. Acyclic nucleoside phosphonates with adenine nucleobase inhibit Trypanosoma brucei adenine phosphoribosyltransferase in vitro. Sci Rep 11:13317. 10.1038/s41598-021-91747-6. PubMed DOI PMC

Gnipová A, Šubrtová K, Panicucci B, Horváth A, Lukeš J, Zíková A. 2015. The ADP/ATP carrier and its relationship to oxidative phosphorylation in ancestral protist trypanosoma brucei. Eukaryot Cell 14:297–310. 10.1128/EC.00238-14. PubMed DOI PMC

Smíd O, Horáková E, Vilímová V, Hrdy I, Cammack R, Horváth A, Lukes J, Tachezy J. 2006. Knock-downs of iron-sulfur cluster assembly proteins IscS and IscU down-regulate the active mitochondrion of procyclic Trypanosoma brucei. J Biol Chem 281:28679–28686. 10.1074/jbc.M513781200. PubMed DOI

Opperdoes FR, Markos A, Steiger RF. 1981. Localization of malate dehydrogenase, adenylate kinase and glycolytic enzymes in glycosomes and the threonine pathway in the mitochondrion of cultured procyclic trypomastigotes of Trypanosoma brucei. Mol Biochem Parasitol 4:291–309. 10.1016/0166-6851(81)90062-1. PubMed DOI

Amoebicidal Effect of COVID Box Molecules against Acanthamoeba: A Study of Cell Death

Chelation of Mitochondrial Iron as an Antiparasitic Strategy

Induction of Programmed Cell Death in Acanthamoeba culbertsoni by the Repurposed Compound Nitroxoline